PTCT insider sale notice: 12,000 shares (~$780K) planned Oct 3, 2025

Rhea-AI Filing Summary

PTC Therapeutics filed a Form 144 notice indicating a proposed sale of 12,000 common shares with an aggregate market value of $780,000.00, to be sold approximately on 10/03/2025 on NASDAQ. The shares are reported as acquired in connection with an option granted on 01/04/2016, with the acquisition/transaction dated 10/03/2025, and the payment method noted as cash. The filing also discloses a prior sale by the same account: 1,667 shares sold on 08/28/2025 for $83,601.72. The filer attests there is no undisclosed material adverse information and includes the standard signature/attestation language.

Positive

• Transaction tied to long‑dated option (option granted 01/04/2016), indicating proceeds stem from exercised equity rather than new dilution
• Planned sale disclosed publicly with an attestation of no undisclosed material information

Negative

• Insider intends to sell 12,000 shares representing a non‑zero insider monetization (~$780,000)
• Prior sale within past two months of 1,667 shares on 08/28/2025 for $83,601.72

Insights

Corporate Governance / Insider Trading

TL;DR: Insider notice for sale of 12,000 shares (~$780K) tied to an option originally granted in 2016.

The Form 144 documents a planned open-market sale of 12,000 common shares on 10/03/2025 with an aggregate market value of $780,000.00, and states the shares were associated with an option granted 01/04/2016. This indicates the sale arises from a long-held equity award rather than an immediate corporate financing event.

The filing also lists a recent sale of 1,667 shares on 08/28/2025 for $83,601.72, showing prior monetization activity. The signer affirms no undisclosed material information, a required representation for Rule 144 notices.

Monitorable item: the approximate sale date 10/03/2025 is the concrete near-term event disclosed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	12000	780000.00	79438094	10/03/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/03/2025	Option Granted - 01/04/2016	Issuer			12000	10/03/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Allan Jacobson 500 Warren Corporate Center Drive Warren NJ 07059	Common	08/28/2025	1667	83601.72

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does PTC Therapeutics' (PTCT) Form 144 disclose?

The filing discloses a proposed sale of 12,000 common shares (~$780,000.00) to be sold on 10/03/2025 on NASDAQ.

How were the shares being sold by the PTCT filer acquired?

The shares are reported as tied to an option granted on 01/04/2016, with acquisition/transaction dated 10/03/2025 and payment in cash.

Has the filer sold any PTCT shares recently?

Yes. The filing reports a prior sale of 1,667 shares on 08/28/2025 for $83,601.72.

Where will the proposed PTCT share sale occur?

The proposed sale is planned to occur on NASDAQ with an approximate date of 10/03/2025.

Does the filing state whether there is undisclosed material information?

The person for whose account the securities are to be sold represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.